Biogen investigates a death possibly linked to its controversial new Alzheimer's drug
Biogen is investigating the death of a 75-year-old patient potentially linked to the company’s new Alzheimer’s drug, which the FDA controversially approved via its accelerated pathway with limited evidence that the drug actually benefits those suffering from the memory wasting disease.
The company told Endpoints News in an emailed statement that it’s carefully reviewing all adverse events reports, medication error reports, and product complaints published in FDA’s Adverse Event Reporting System, “including the fatal case of a 75-year-old patient whose cause of death remains under investigation and who was diagnosed during hospitalization with cerebral edema thought to be ARIA-E. We continue to work with the reporting physician as well as global regulators to further understand the case. Alzheimer’s disease is complex, and patients affected by this devastating disease often suffer from other serious medical conditions.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.